J&J in ascendancy as DES study gives favourable results for sirolimus
This article was originally published in Clinica
Executive Summary
In an otherwise nervy industry sector, Johnson & Johnson now has at least two reasons to be optimistic. Two weeks after a study presented at the European Society of Cardiology (ESC) brightened the outlook for drug-eluting stent use, a new meta-analysis has acclaimed the firm's sirolimus-eluting stent, Cypher.